Mantle cell lymphoma: evolving novel options.
Mantle cell lymphoma (MCL) represents only 6% of non-Hodgkin's lymphoma but is one of the most active fields of clinical investigation. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and rituximab. Unfortunately, no standard therapy has been defined, and most patients eventually relapse. An impressive number of novel agents are currently being tested, the bulk of which are biologic agents or targeted therapies. Bortezomib is the first in class of proteasome inhibitors and the first new agent to be approved in relapsed/refractory MCL. Other small molecules have shown encouraging activity, including mTOR and Bcl-2 inhibitors, novel antibodies, and new cytotoxic agents. Future trials will also benefit from new molecular approaches through pharmacogenomics.
Goy
Andre
A
Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA. agoy@humed.com
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D016499:Radioimmunotherapy
J Clin Oncol. 2003 May 1;21(9):1740-5
12735303
J Clin Oncol. 2007 May 1;25(13):1741-6
17389337
Blood. 2007 May 15;109(10):4441-9
17227835
Oncology (Williston Park). 1998 Oct;12(10 Suppl 8):49-55
9830633
J Clin Oncol. 2006 Jan 1;24(1):166-73
16330674
Blood. 2003 Oct 15;102(8):3003-9
12842981
Leuk Lymphoma. 2001 Sep-Oct;42(5):1015-22
11697618
Blood. 2006 Mar 15;107(6):2271-8
16332971
Blood. 2004 Aug 1;104(3):795-801
15090459
J Clin Oncol. 2006 Jul 1;24(19):3113-20
16754936
J Clin Oncol. 2005 Aug 10;23(23):5347-56
15983389
Blood. 2002 May 1;99(9):3158-62
11964278
Clin Cancer Res. 2006 Sep 1;12(17):5165-73
16951235
J Clin Oncol. 2002 Mar 1;20(5):1288-94
11870171
Mod Pathol. 2001 Nov;14(11):1133-40
11706075
Blood. 2006 Apr 15;107(8):3407
16597597
J Clin Oncol. 1998 Feb;16(2):579-83
9469344
Blood. 2004 Oct 15;104(8):2269-71
15166030
Nat Med. 2005 Sep;11(9):986-91
16116429
Nat Rev Cancer. 2004 May;4(5):349-60
15122206
Cancer Cell. 2003 Feb;3(2):185-97
12620412
J Clin Oncol. 2005 Feb 1;23(4):667-75
15613697
Ann Hematol. 2007 Feb;86(2):101-5
17089127
J Clin Oncol. 2005 Feb 1;23(4):676-84
15613699
Blood. 2007 Jan 15;109(2):399-404
17003373
J Clin Oncol. 2005 Oct 1;23(28):7013-23
16145068
J Clin Oncol. 2005 May 20;23(15):3383-9
15908650
J Clin Oncol. 2003 Dec 1;21(23):4407-12
14645431
Blood. 2005 Dec 15;106(13):4315-21
16123218
Blood. 2004 Nov 15;104(10):3064-71
15284112
Curr Opin Immunol. 2006 Apr;18(2):206-13
16464564
Blood. 2006 Sep 1;108(5):1668-76
16645163
Leukemia. 2002 Apr;16(4):587-93
11960337
Blood. 2008 Jan 15;111(2):558-65
17962512
Leukemia. 2007 Mar;21(3):524-8
17268531
Br J Haematol. 2006 Aug;134(4):391-8
16882131
J Clin Oncol. 2005 Sep 10;23(26):6364-9
16155021
J Clin Oncol. 2006 Oct 20;24(30):4867-74
17001068
J Immunol. 2003 Jul 1;171(1):88-95
12816986
Eur J Haematol. 2006 Jan;76(1):42-50
16343270
Cancer. 2003 Feb 1;97(3):586-91
12548600
Cancer Res. 2003 Oct 1;63(19):6174-7
14559800
J Clin Oncol. 1998 Dec;16(12):3803-9
9850025